Lead a Payer & Distribution consulting firm serving emerging US, European and Canadian life science manufacturers who are often developing and preparing to launch their 1st product into the USA marketplace.

Manufacturers seek our strategic and tactical Market Access services during Pre-launch Planning and/or the post-FDA Launch Implementation Phases.
- Planning: Reimbursement and Distribution
- Market Research: Product X and competitive products
- Payer Launch: National Account Teams

Provide strategic vision, specialty pharmacy/distribution and market access strategy consulting for biopharma clients who are preparing or launching an NDA, BLA, or 510k prescription product into the US marketplace.
 Lead new business development, proposal development, bid submissions and client engagements
- Conduct and develop strategic pricing, competitive landscape analysis, product positioning, copay/coinsurance analyses, qualitative and quantitative PBM/payer research, value proposition development, contracting strategy
 Leadership roles in strategic value propositions, US price analysis, research, planning and competitive positioning
 Lead and provide direction to 5 – 7 staff on proposal frameworks and delivery of client commercialization projects
 Serve as key point of contact for project delivery and follow-up to ensure client satisfaction
 Lead, execute and deliver on client projects providing guidance to internal consultants and analysts

> Developed payer strategy, established pricing and Gross-to-Net model for orphan Cystic Fibrosis product
> Negotiated optimal specialty pharmacy and data network agreements
> Developed payer value proposition and communication tools. i.e.: AHFS DI monograph, Specialty Pharmacy and Payer decks, and Predictive Payer Modeling tool
> Launched Product X and established client corporate recognition with payers
> Tactics resulted in >70% payer formulary positioning exceeding corporate forecasts

Market Access, Great Lakes & Northeast.
> Created formulary access for ZENPEP in orphan disease state of Cystic Fibrosis
> Gained positive formulary positions at Aetna, CIGNA, Emblem Health NY, BCBS MA, Excellus, Highmark, Gateway, Member Health, Horizon NJ Health.
> Propelled market share growth to > 25%.
> Created cost model which resulted in increased formulary wins and saves.

Lead Market Access strategy and tactical initiative development
> Advised C level and Sr management of payer marketing strategies including AWP & WAC pricing, Gross-To-Net analysis, and key industry legislative events.
> Launched Product X to national PBMs and national payers.
> Executed payer initiatives resulting in positive formulary positioning exceeding corporate forecasts.
> Contributed content, advice, and positioning of market information for public press communiqué.

Multiple roles of increasing responsibility.
Companies included:
- Celltech Pharmaceuticals, Inc. (Acquired by UCB in 2004)
- Medeva Pharmaceuticals, Inc. (Acquired by Celltech in 1996)
- Adams Laboratories, Inc. (Acquired by Medeva in 1993)

> Created formulary access while maximizing profitability: CVS, Express Scripts, Aetna, CIGNA, Humana, many BCBS accounts.
> Launched KEPPRA, KEPPRA XR, CIMZIA, XYZAL, VALSTAR, ZAROXOLYN, TUSSIONEX, SEMPREX-D, HUMIBID and many others.